Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONStandard

TECENTRIQ HYBREZA

ATEZOLIZUMAB AND HYALURONIDASE-TQJS

Standard Dose
125MG;2000UNITS PER ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary

Approval overview TECENTRIQ HYBREZA is listed in Drugs@FDA under application 761347 (BLA).

Review priority: PRIORITY Marketing status: Prescription Active ingredient ATEZOLIZUMAB AND HYALURONIDASE-TQJS Form and strength INJECTABLE;INJECTION - 125MG;2000UNITS PER ML Sponsor GENENTECH INC Submission history Latest submission status date: 2025-11-24 00:00:00.

Structured Monograph

Clinical summary

Approval overview TECENTRIQ HYBREZA is listed in Drugs@FDA under application 761347 (BLA). Review priority: PRIORITY Marketing status: Prescription Active ingredient ATEZOLIZUMAB AND HYALURONIDASE-TQJS Form and strength INJECTABLE;INJECTION - 125MG;2000UNITS PER ML Sponsor GENENTECH INC Submission history Latest submission status date: 2025-11-24 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.